SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.70), $0.06 worse than the analyst estimate of ($1.64). Revenue for the quarter came in at $8.65 million versus the consensus estimate of $8.75 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.